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INTRODUCTION Rationale
Fracture healing is a complex physiological process, 1 the process of which is to restore the continuity and function of the damaged bone. 2 Impaired healing delays the rehabilitation process and leads to delayed union, non-union, and defect, which will increase the need for care and cause serious complications. It will deeply affect the quality of life for the patients. Meanwhile, the related costs will cause a heavy economic burden to the society and family. Thus, identifying strategies to prevent delayed unions and non-unions in individuals with impaired bone healing, as well as accelerate the rate of healing in healthy individuals, is essential. 3 Parathyroid hormone (PTH) is a key systemic regulator of calcium and phosphate metabolism. 4 To date, there are two kinds of PTH analogues, PTH 1-84, and teriparatide. PTH 1-84 is a full-length recombinant human PTH. Teriparatide is a synthetic polypeptide hormone consisting of the 1-34 fragment of PTH, which retains most of the biological activities of PTH. 5 6 Both are approved for the treatment of osteoporosis. 7 8 It has been determined that intermittent administration of PTH analogues exerts anabolic effect on bone, increases bone mass and reduces bone loss, leading to an increase in bone formation. [9] [10] [11] [12] [13] [14] Owing to their anabolic effect, there is an increasing interest in its potential in promoting the process of bone healing. In animal experiments, several studies have been demonstrated that PTH analogues can produce an anabolic effect during the whole remodeling stage of bone healing. [15] [16] [17] [18] [19] However, in clinical studies, the results are in conflict. Some studies indicate that daily intermittent systemic administration of PTH analogues provides a beneficial effect on fracture healing. [20] [21] [22] [23] [24] [25] [26] But some trials show that PTH analogues have no effect to increase fracture healing or decrease pain. [27] [28] [29] [30] Since evidence-based evaluation and relative reviews will be conducted to further identify potentially eligible trials. Moreover, ClinicalTrials.gov (http://www.clinicaltrials.gov) will be searched to identify studies of interest not yet published.
Search strategy
Search strategies will be developed using medical subject headings (MeSH) as well as text words associated with terms relevant to "teriparatide", "parathyroid hormone", together with "randomized controlled trial". Preliminary search strategies used in MEDLINE, EMBASE, and CENTRAL are provided in online supplementary file 1. The searches will be conducted by two authors independently (SL, HL).
Study records

Data management
Literature search results are managed through EndNote X7, which will be used to remove duplicate records.
All extracted data are stored in a Microsoft Excel spreadsheet.
Selection process
The process of study selection will be shown in a PRISMA-compliant flow chart (Figure 1 ), all carried out by two authors (SL, HL), with a third author (ZL) available to help resolve any disagreement. As a first step, SL and HL will independently review titles and abstracts of all retrieved articles and exclude the studies that obviously do not fulfill the eligibility criteria. And then, each author will further review the full texts of the remaining studies to determine whether they meet the eligibility criteria. If multiple reports are found to the same study, the results of that study will be collated together.
Data collection process
Two authors (SL, HL) will carefully and independently extract data from all eligible publications in duplicate. Disagreements will be resolved through discussion, and a third author (YW) if necessary. For missing data, we will seek supplementary appendixes and contact study authors via email to obtain the original data. We will allow a delay of 12 weeks to receive a response following two reminder emails at 4 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   6 and 8 weeks.
Data items
The following data will be extracted: (1) study characteristics (eg, author, journal, year, blinding, randomization, group design, etc.); (2) participant characteristics (eg, age, sex, ethnicity, height, body weight, etc.); (3) intervention details (eg, intervention, comparator, cointervention, dosage, frequency, route, duration, etc.); (4) outcome measures (eg, sample sizes, means and SDs, adverse events, etc.).
Outcomes and prioritization
The primary outcome in this study will be fracture union. Fracture union, as determined by radiography, which is defined as a callus is present bridging at least three of four cortices on orthogonal radiographs.
33
The secondary outcomes will include functional recovery and adverse events. Functional recovery is defined as an improvement in mobility, and will be assessed by scales or tests. Adverse events will include nausea, sweating, hypercalcemia, headache, dizziness, depression and other adverse events related to parathyroid hormone analogues.
Risk of bias in individual studies
Two reviewers (SL, HL) will independently assess risk of bias for each included study. Any disagreement will be resolved through discussion or will be judged by a third reviewer (PT). The tool developed by the Cochrane Collaboration will be used to assess the risk of bias in the following seven categories: (1) random-sequence generation (selection bias); (2) allocation concealment (selection bias); (3) blinding of participants and personnel (performance bias); (4) blinding of outcome assessment (detection bias); (5) incomplete outcome data (attrition bias); (6) selective reporting (reporting bias); (7) other bias. 34 Each item will be classified as having either a high, low or unclear risk of bias, and reasons for each assessment will be documented.
Data synthesis
For dichotomous outcomes, such as adverse events, a risk ratio (RR) with 95% confidence interval (CI) will be reported. For continuous outcomes, such as difference in mean function score, a standardized mean difference (SMD) will be used to express the result.
Meta-analysis is performed by a random-effect model, which provides more conservative estimated If substantial heterogeneity (I² >50%) is present and the number of included studies is sufficient, subgroup analyses will be used to identify reasons for heterogeneity, based on the following variables: (1) upper limb, lower limb, or axial skeleton; (2) short-term treatment (duration < 6 moths) or long-term treatment (duration > 6 months); (3) low risk or high risk. In addition, sensitivity analyses will be conducted to examine the robustness of our analysis by omitting specific trials from the overall analysis.
If quantitative synthesis is not appropriate, we will just perform a narrative, qualitative summary and the information will be presented using text and tables.
Meta-bias
If 10 or more studies are included in the meta-analysis, small-study effects for primary and secondary outcomes will be qualitatively analyzed using funnel plots as well as qualitatively analyzed using Egger tests. 37 38 If available, reporting bias is assessed by comparing the study findings with its protocol.
Confidence in cumulative evidence
The quality of the evidence for each outcome will be assessed using the Grading of Recommendations Assessment Development and Evaluation (GRADE) approach. 39 This approach will assess the risk of bias;
consistency; directness; imprecision and publication bias. The overall quality of evidence will be rated as high, moderate, low or very low. This process will be performed using the GRADEpro online software (http://gradepro.org).
ETHICS AND DISSEMINATION
Since this study does not include confidential personal data and does not involve patient intervention, ethical approval is not required. The results of this study will be disseminated in a peer-reviewed journal and presented at a relevant conference.
Contributors: PT and YW are the guarantors. SL, HL, and ZL contributed to the conception and design of this study protocol. SL registered the protocol with the PROSPERO database and edited the draft protocol.
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Data collection process 11c Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators 5 Data items 12 List and define all variables for which data will be sought (such as PICO items, funding sources), any pre)planned data assumptions and simplifications
5)6
Outcomes and prioritization 13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale 6
Risk of bias in individual studies
14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis 
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Risk of bias in individual studies
14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis 6
Data synthesis 15a Describe criteria under which study data will be quantitatively synthesised 6 15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I 2 , Kendall's τ) 6 15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta)regression) 6)7 15d If quantitative synthesis is not appropriate, describe the type of summary planned 7 Meta)bias(es)
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